

**Eun Ah Choi**  
**Senior Vice President**  
**U.S. Listing Qualifications & Market Surveillance**

By Electronic Mail

August 9, 2022

Division of Corporation Finance  
U.S. Securities and Exchange Commission  
100 F Street, N.E.  
Washington, D.C. 20549

Division of Corporation Finance:

This is to certify that on August 2, 2022 The Nasdaq Stock Market LLC (the "Exchange") received from bioAffinity Technologies, Inc. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following securities:

**Common Stock, par value \$0.007**

**Tradeable Warrants to purchase Common Stock**

We further certify that the securities described above has been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

